FOLH1 and posterior cortical atrophy: Numerous PET imaging agents that delineate PSMA expression have been tested in the clinic, and clever design of the radiotracers has facilitated the transition toward PSMA-targeted radionuclide diagnosis and therapy (68Ga-PSMA-11, 68Ga-gozetotide;14,15177Lu-PSMA-617, Locametz®, Novartis, PluvictoTM, Novartis16).17,18 Whilst high expression levels in most PCa phenotypes mean that PSMA is the current biomarker of choice when developing radiotracers for imaging and therapy, several drawbacks remain.